SEOUL, South Korea, July 17, 2025 /PRNewswire/ — DeepQure announced today that South Korea’s Ministry of Food and Drug Safety (MFDS) has approved a clinical trial of HyperQure™ RDM System, the company ...

AstraZeneca announced that baxdrostat, a selective aldosterone synthase inhibitor, met its primary and all secondary ...

Struggling to control high BP? Learn about resistant hypertension, its causes, and expert-approved ways to manage it. Get ...

Resistant hypertension, especially for prolonged periods, is accompanied by a substantial increase in the overall risk of cardiovascular and renal events, owing to the common coexistence of other ...

In addition to taking medication, paying attention to these habits can help maintain healthy blood pressure levels..resistant ...

AstraZeneca’s Phase III BaxHTN trial shows that baxdrostat significantly lowers systolic blood pressure in resistant ...

Baxdrostat meets primary and all secondary endpoints in BaxHTN phase III trial in patients with uncontrolled or treatment resistant hypertension: Cambridge, UK Wednesday, July 16, ...

Characterization of resistant hypertension: association between resistant hypertension, aldosterone, and persistent intravascular volume expansion. Arch Intern Med 2008; 168 : 1159–1164.

The phase 3 BaxHTN trial has been evaluating two doses of the drug in patients with uncontrolled hypertension being treated ...

AstraZeneca Plc (NASDAQ:AZN) released high-level results from the Cardiac Amyloid Reaching for Extended Survival (CARES) ...

Resistant hypertension is defined as high BP that is not adequately controlled to less than 140/90 mmHg with three antihypertensive drugs given at optimal dosages. Ideally, ...

AstraZeneca said on Monday its experimental drug baxdrostat significantly lowered blood pressure in a late-stage trial of ...